Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation (OPTILTH)

January 25, 2019 updated by: Rennes University Hospital
Prospective, non-randomized, open Pharmacokinetic-Pharmacogenetic-Pharmacodynamic monocentric study. Donor and recipient CYP3A5 genotype and recipient ABCB1 will not be communicate to clinicians or patients during the study.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Rennes, France, 35033
        • CHU de Rennes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient with liver tranplantation

Description

Inclusion Criteria:

  • Adults over 18
  • Liver transplant recipients
  • Treated with an immunosuppressive protocol with tacrolimus
  • Informed on the study and who did not refuse to participate

Exclusion Criteria:

  • Patients who participate in a study with procedures incompatible with the present study.
  • Patients with legal protection/deprived of liberty.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prediction of calcineurin inhibition, responsible for the immunosuppressive effect
Time Frame: Week 24
Assessement of the relationships between tacrolimus dosage, whole-blood and intracellular concentrations
Week 24
Prediction of calcineurin inhibition, responsible for the immunosuppressive effect
Time Frame: Week 24
Assessement of the relationships between intracellular concentrations of tacrolimus and calcineurin activity
Week 24
Prediction of calcineurin inhibition, responsible for the immunosuppressive effect
Time Frame: Week 24
Assessement of the relationships between donor and recipient CYP3A5 and ABCB1 genotypes and dose/concentration of tacrolimus
Week 24
Prediction of calcineurin inhibition, responsible for the immunosuppressive effect
Time Frame: Week 24
Assessement of the relationships between intracellular concentration of tacrolimus and/or calcineurin activity and ACR, in patients treated with immediate release or modified-release formulation of tacrolimus
Week 24

Secondary Outcome Measures

Outcome Measure
Time Frame
Study of impact of pharmacogenetic and demographic data on tacrolimus intracellular concentration
Time Frame: Week 24
Week 24
Evaluation of the role of the measurement of intracellular concentration as a longitudinal biomarker in preventing acute cellular graft (ACR)
Time Frame: Week 24
Week 24
Study of variability of tacrolimus intracellular concentration according to its pharmaceutic form (immediate or sustained release)
Time Frame: Week 24
Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rennes University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 31, 2015

Primary Completion (Actual)

November 29, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

August 16, 2016

First Submitted That Met QC Criteria

August 19, 2016

First Posted (Estimate)

August 24, 2016

Study Record Updates

Last Update Posted (Actual)

January 28, 2019

Last Update Submitted That Met QC Criteria

January 25, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 35RC13_8962_OPTILTH

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Transplantation

Clinical Trials on Pharmacokinetic-pharmacodynamic model in liver transplantation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe